P100 Latency Prolongation and Amplitude Reduction in Patients with RRMS
In a study of 83 patients with relapsing-remitting MS over two years, 43.4% developed prolonged P100 latency, linked to a higher relapse rate (OR 2.91, p = 0.005). Additionally, 56.6% showed reduced amplitude, associated with greater disability, but these findings were not robust after multiple comparisons and adjustments.
- Most relevant to
- Neurologist, Ophthalmologist
Why it matters
These exploratory results suggest a potential link between VEP changes and disease activity or disability in RRMS, which could enhance monitoring strategies.
What this does not prove
The rarity of defined PIRA events limited inferential conclusions, and the study needs further prospective validation to confirm findings.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Observational
- Participants / samples
- 83 · total patients analyzed
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- RRMS
- Publication date
- 2026-09-11
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Not classified
Original sources
- Primary evidenceVisual Evoked Potentials Linked to MS Relapse and Disability ↗
Supporting passages (10)
study designThis exploratory study aimed to evaluate the clinical utility of serial VEP assessments in patients with relapsing-remitting MS (RRMS) by examining the associations between temporal changes in latency and amplitude and concurrent markers of disease activity and disability.
subjectsWe retrospectively analyzed 83 patients with RRMS from three centers who underwent at least two pattern-reversal VEP assessments
sample sizeMaterials and Methods: We retrospectively analyzed 83 patients with RRMS from three centers who underwent at least two pattern-reversal VEP assessments ≥ 1 year apart.
sample size basisMaterials and Methods: We retrospectively analyzed 83 patients with RRMS from three centers who underwent at least two pattern-reversal VEP assessments ≥ 1 year apart.
relevant ms typesRRMS
publication date2026-09-11
follow upOver a median follow-up of 2 years
findingsResults: Over a median follow-up of 2 years, 43.4% of patients developed P100 latency prolongation, which was independently associated with a higher annualized relapse rate during the same interval (odds ratio [OR] 2.91, p = 0.005; area under the curve (AUC) 0.72 for concurrent on-study relapse activity), an association that persisted after adjustment for DMT efficacy tier, but not with disability worsening.
findingsIn contrast, 56.6% of patients exhibited amplitude reduction, which was associated with greater disability accumulation at the group level, with higher EDSS scores at follow-up despite similar baseline values (p < 0.05); the corresponding inverse correlation between amplitude decline and EDSS change was only nominally significant (ρ = -0.231, p = 0.036), did not survive correction for multiple comparisons, and was attenuated after adjustment for baseline EDSS.
limitationsFormally defined PIRA events were rare (n = 3), precluding inference.
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.